comprehensive
LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
The deal includes up to another $400 million in payments if certain milestones are met.
advertisement
Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Petition to FDA: Get the lead out of consumer hair dyes
Next article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Dobbs anniversary: the lost opportunity of abortion as health care
